Last updated: May 28, 2026
Hydrochlorothiazide and Metoprolol Tartrate Suppliers: Who Manufactures API, Finished Dosage, and Key Packaging Streams?
This supplier map covers the two active ingredients hydrochlorothiazide and metoprolol tartrate across API manufacturing, contract manufacturing of tablets, and common downstream packaging supply.
Core point: the supply chain is typically split between (1) API manufacturers producing active ingredient under DMF/CEP frameworks, and (2) finished dosage manufacturers sourcing API and producing tablets for US and global markets, often with multiple qualification pathways.
Which companies supply hydrochlorothiazide API and generic tablets?
Hydrochlorothiazide API supply: typical supplier set
Hydrochlorothiazide (HCTZ) is an established, widely generic diuretic. Supply is dominated by global chemical API manufacturers with US DMF/EDMF coverage and multiple global production sites.
Common API supplier profile (by business role)
- Bulk/API chemical producers with DMF filings for hydrochlorothiazide
- High-volume generic API manufacturers serving tablet and combination products
- Regional API producers in India and China supplying global generics, including US-facing programs
Finished dosage tablet supply: typical sourcing
Finished HCTZ tablets are typically produced by:
- Large US and global contract development and manufacturing organizations (CDMOs) that run ANDA product supply contracts
- Generic pharmaceutical companies producing in-house dosage forms and then selling through distribution channels
- Co-packers supporting bottling/blister packaging and labeling services
Hydrochlorothiazide combo tablet supply relevance
HCTZ frequently appears in fixed-dose combinations (often with ACE inhibitors or ARBs). Those combination products pull additional supplier demand for:
- HCTZ API
- Combination tablet contract manufacturing
- Packaging and labeling services sized to launch schedules
Which companies supply metoprolol tartrate API and generic tablets?
Metoprolol tartrate API supply: typical supplier set
Metoprolol tartrate is also a well-established generic beta-blocker. API supply is carried by multiple global manufacturers with capabilities for chiral synthesis and salt formation control.
Common API supplier profile
- Manufacturers specializing in cardiovascular small molecules
- Chiral chemistry and salt-form control capability
- DMF or relevant regulatory documentation for API commercialization
Finished dosage tablet supply
Tablet manufacturing is usually handled by:
- Large generic and CDMO tablet lines with documented batch consistency
- Companies that run immediate-release tablet processes and packaging through finished goods release
Metoprolol tartrate risk factors that affect supplier choice
- Salt form consistency and polymorph/solvate control
- Impurity profile control (process and storage stability)
- Batch-to-batch consistency for compressed tablet performance
What suppliers can cover both hydrochlorothiazide and metoprolol tartrate in combination products?
How supply consolidates for combination coverage
If the end product is a combination tablet (not always marketed as a single capsule/tablet with these two actives in the US), a consolidated supplier set usually looks like:
- One or more APIs suppliers for each actives ingredient
- One contract manufacturer qualified to compress both APIs in the same tablet line
- A packaging house that can support bottle and blister streams with the required labeling formats
Common operational pattern
Most companies do not rely on a single vendor for both actives. Instead, they qualify multiple APIs sources per active ingredient, while locking in a primary finished dosage manufacturer and packaging suppliers.
What is the API regulatory-facing supplier route: DMF, CEP, and ANDA readiness?
Typical documentation and qualification
For both HCTZ and metoprolol tartrate, supplier qualification commonly depends on:
- US DMF linkage to the finished dosage ANDA
- CEP/European regulatory documentation where applicable for global filings
- Updated stability and impurity specifications aligned to the product dossier
Where supplier constraints show up
- If an ANDA product is already established, supply typically tracks to the originally referenced API dossier or closely comparable filings.
- For new launches, supplier selection often occurs ahead of formulation development and process validation, then finalizes during tech transfer.
Which finished dose manufacturers and CDMOs produce HCTZ and metoprolol tartrate tablets?
Finished dosage manufacturing footprint
Tablet manufacturing is widely distributed, with:
- High-capacity generic tablet manufacturers supplying multiple strengths
- CDMOs offering compression, coating, and packaging services
- Secondary packaging providers supplying bottling and blister packs
How to evaluate a finished dosage supplier quickly
High-intent screening usually focuses on:
- Experience with immediate-release tablets and high-volume compression lines
- Ability to support multiple strengths and packaging configurations
- Proven batch release and quality system maturity
Which packaging suppliers are typically used for hydrochlorothiazide and metoprolol tartrate products?
Packaging streams
Common packaging supply segments for generic tablet products:
- Bottles (HDPE) with desiccant options depending on humidity sensitivity
- Blister packs for unit-dose market preferences
- Secondary cartons, inserts, and labeling formats
Release and serialization dependencies
US-facing distribution may require:
- Consistent labeling and imprint standards
- Barcode formats and distribution-ready carton configurations
- Serialization readiness where contract scope includes aggregation labeling
What is the competitive supplier landscape for hydrochlorothiazide and metoprolol tartrate?
Supplier consolidation and multi-sourcing
Because both molecules are mature:
- Supplier landscapes tend to be broad for API
- Finished dosage supply is more concentrated among a smaller set of CDMOs and generic manufacturers with validated tablet lines
Why that matters
Multi-sourcing reduces launch delays, but increases diligence needs for:
- API change control
- impurity/spec alignment
- stability demonstration in the finished product
How do supplier qualification, quality agreements, and change control work for these APIs?
Qualification workflow
Typical qualification steps include:
- Incoming API qualification against defined specs
- Document review for DMF or equivalent regulatory basis
- Quality agreements governing audit rights, deviations, and batch disposition
Change control triggers
For HCTZ and metoprolol tartrate, supplier switching or process changes often trigger:
- Tech transfer, stability continuation, and analytical bridging
- Regulatory updates to the ANDA dossier if required by filing strategy
What generic launch scenarios depend on supplier availability for HCTZ and metoprolol tartrate?
Scenario A: ANDA launch using an established API dossier
- Lower regulatory friction if API is already referenced or closely aligned
- Supplier continuity is critical to avoid discontinuation risk
Scenario B: Launch with a different API source
- Requires stronger comparability and often additional bridging work
- Timing depends on analytical readiness and change control approval windows
Key Takeaways
- Hydrochlorothiazide and metoprolol tartrate generally support a broad API supplier base, with qualification typically driven by DMF/CEP documentation and impurity/spec controls.
- Finished dosage tablet supply is usually handled by a smaller set of high-throughput tablet manufacturers and CDMOs, with packaging supported by dedicated packaging houses.
- The most time-sensitive constraint is not API availability in general, but regulatory-facing dossier alignment and finished-dose tech transfer readiness.
FAQs
1) Can a generic manufacturer qualify multiple hydrochlorothiazide API suppliers under one ANDA?
Yes, multi-source qualification is common, but each API source must meet the same quality specs and dossier linkage requirements.
2) What quality parameters most often drive supplier rejection for metoprolol tartrate?
Impurity profile, salt form controls, and stability under defined storage conditions.
3) Are blister packaging providers interchangeable for tablet products?
Not automatically. Labeling format, carton configuration, and stability handling need alignment to finished product specs.
4) What is the biggest timeline risk when switching API suppliers for either active ingredient?
Analytical bridging and stability confirmation for the finished dosage, plus dossier change control timing.
5) Do combination tablets impact supplier selection for hydrochlorothiazide and metoprolol tartrate?
Yes. Combination manufacturing requires line suitability for both actives and packaging synchronization for launch volumes.
References
- FDA. ANDA Regulatory Guidance and Application Requirements. US Food and Drug Administration.
- FDA. Drug Master Files (DMF) Guidance. US Food and Drug Administration.
- EMA. Certificates of Suitability (CEP) for APIs. European Medicines Agency.
